Early trial results presented at @AACR Annual Meeting 2026 suggest a CAR T-cell therapy can prevent disease progression in people with high-risk smoldering myeloma. Learn more: https://t.co/zBG3a7FqHh #AACR26 https://t.co/mWSHzesCaX